DM199 for Pregnancy Complications

Summary

This entry was submitted in error by DiaMedica Therapeutics, Inc. and was not authorized by any of the trial Investigators or study sponsor (Stellenbosch University). The clinical trial, DM199 for Pregnancy Complications, was prospectively registered with the Pan African Clinical Trials Registry (PACTR202404895013782), in accordance with ICMJE and WHO requirements. This listing serves as the primary and authoritative registration record for this investigator-initiated study.

Timeline

Start

2025-05

Primary completion

2025-05

Completion

2025-05

Outcome

Met primary endpoint

Stopped: “This entry was unauthorized and has been withdrawn.”

release “The study achieved pre-specified safety and efficacy endpoints for the Part 1a dose escalation phase” diamedica.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rinvecalinase Alfa	Protein / enzyme biologic	—	—

Indications